Biotech startup 23andMe lays off 40% of employees and stops drug devel

Biotech startup 23andMe lays off 40% of employees and stops drug development

- DNA testing startup to lay off 40% of employees - Layoffs could affect 200+ employees at 23andMe - The startup is trying to stabilize a loss-making business - Also, 23andMe will close its drug development business - It was already testing two drugs on humans - 23andMe will try to sell promising drugs - Previously, drug development was its key bet - 23andMe still wants to license its data - It's about genetic data for pharmaceutical companies. - The startup is still trying to find additional partners - No new partners have emerged in the year since the GSK deal - The startup has had 5 rounds of layoffs since 2023 - New restructuring will save it up to $35 mln/year - 23andMe's core consumer business is unprofitable

New biosensor in seatbelt monitors drivers' condition

Scientists from the National University of Singapore and Tsinghua University have developed a new biosensor that can monitor the condition of drivers and pilots. It has been built into the seat belt. The new sensor is designed to cope with problems caused by vibrations in vehicles. It uses special materials and conductive filaments that help it pick up biosignals even through clothing. The bio-se

New Hope for Epilepsy Sufferers: Glasses That Block Harmful Light Waves

Revolutionary Glasses for Epilepsy Relief: Researchers from the University of Glasgow and the University of Birmingham have developed a groundbreaking prototype of glasses that could significantly improve the lives of those with light-sensitive epilepsy. The glasses feature liquid crystal lenses that block over 98% of light in the 660-720 nm wavelength range, which is known to trigger seizures in

Biotech startup 23andMe lays off 40% of employees and stops drug development

Recommended

New biosensor in seatbelt monitors drivers' condition

New Hope for Epilepsy Sufferers: Glasses That Block Harmful Light Waves